CASI Pharmaceuticals Stock Today


USD 1.97  0.02  1.01%   

Market Performance
0 of 100
Odds Of Distress
Less than 27
CASI Pharmaceuticals is trading at 1.97 as of the 2nd of December 2022. This is a -1.01% down since the beginning of the trading day. The stock's open price was 1.99. CASI Pharmaceuticals has about a 27 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for CASI Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of December 2020 and ending today, the 2nd of December 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of June 1996
Health Care
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland. The company has 13.61 M outstanding shares of which 90.6 K shares are currently shorted by private and institutional investors with about 3.08 trading days to cover. More on CASI Pharmaceuticals

Moving together with CASI Pharmaceuticals

+0.86BEAMBeam TherapeuticsInc Normal TradingPairCorr

Moving against CASI Pharmaceuticals

-0.56ILMNIllumina Downward RallyPairCorr
-0.51JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr

CASI Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. CASI Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding CASI Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CASI Pharmaceuticals generated a negative expected return over the last 90 days
CASI Pharmaceuticals may become a speculative penny stock
CASI Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 30.17 M. Net Loss for the year was (36.65 M) with profit before overhead, payroll, taxes, and interest of 17.61 M.
CASI Pharmaceuticals currently holds about 24.57 M in cash with (26.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
CASI Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 33.0% of the company shares are held by company insiders
CEOKen Ren
Fama & French Classification
Average Analyst Recommendation
Analysts covering CASI Pharmaceuticals report their recommendations after researching CASI Pharmaceuticals' financial statements, talking to executives and customers, or listening in on CASI Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering CASI Pharmaceuticals. The CASI Pharmaceuticals consensus assessment is calculated by taking the average forecast from all of the analysts covering CASI Pharmaceuticals.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of CASI Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of CASI Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted14.7 M13.6 M
Significantly Up
Slightly volatile
Weighted Average Shares14.7 M13.6 M
Significantly Up
Slightly volatile
Current Liabilities14.2 M13.2 M
Significantly Up
Slightly volatile
Total Liabilities58 M53.8 M
Significantly Up
Slightly volatile
Gross Margin60.3358.3764
Sufficiently Up
Slightly volatile
Total Debt1.2 M1.2 M
Sufficiently Up
Slightly volatile
Asset Turnover0.210.2268
Significantly Down
Current Assets66.9 M62 M
Significantly Up
Slightly volatile
Total Assets149.2 M138.3 M
Significantly Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of CASI Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
CASI Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to CASI Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CASI Pharmaceuticals' financial leverage. It provides some insight into what part of CASI Pharmaceuticals' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on CASI Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how CASI Pharmaceuticals deploys its capital and how much of that capital is borrowed.
CASI Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.9 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. CASI Pharmaceuticals has a current ratio of 3.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist CASI Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, CASI Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CASI Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CASI Pharmaceuticals to invest in growth at high rates of return. When we think about CASI Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(27.55 Million)
CASI Pharmaceuticals (CASI) is traded on NASDAQ Exchange in USA and employs 176 people. CASI Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 27.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CASI Pharmaceuticals's market, we take the total number of its shares issued and multiply it by CASI Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. CASI Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 13.61 M outstanding shares of which 90.6 K shares are currently shorted by private and institutional investors with about 3.08 trading days to cover. CASI Pharmaceuticals currently holds about 24.57 M in cash with (26.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
Check CASI Pharmaceuticals Probability Of Bankruptcy
CASI Pharmaceuticals retains a total of 13.61 Million outstanding shares. CASI Pharmaceuticals retains considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check CASI Pharmaceuticals Ownership Details

CASI Pharmaceuticals Stock Price Odds Analysis

In reference to a normal probability distribution, the odds of CASI Pharmaceuticals jumping above the current price in 90 days from now is about 78.02%. The CASI Pharmaceuticals probability density function shows the probability of CASI Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4547 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, CASI Pharmaceuticals will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. CASI Pharmaceuticals is significantly underperforming NYSE Composite.
  Odds Below 1.97HorizonTargetOdds Above 1.97
21.93%90 days
Based on a normal probability distribution, the odds of CASI Pharmaceuticals to move above the current price in 90 days from now is about 78.02 (This CASI Pharmaceuticals probability density function shows the probability of CASI Pharmaceuticals Stock to fall within a particular range of prices over 90 days) .

CASI Pharmaceuticals Historical Income Statement

CASI Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting CASI Pharmaceuticals's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of CASI Pharmaceuticals revenue and expense. CASI Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
CASI Pharmaceuticals Gross Profit is most likely to increase significantly in the upcoming years. The last year's value of Gross Profit was reported at 17.61 Million. The current Interest Expense is estimated to increase to about 24.1 K, while Consolidated Income is projected to decrease to (36.8 M). View More Fundamentals

CASI Pharmaceuticals Stock Against Markets

Picking the right benchmark for CASI Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in CASI Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for CASI Pharmaceuticals is critical whether you are bullish or bearish towards CASI Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in CASI Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Headlines Timeline Now


Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

CASI Pharmaceuticals Corporate Directors

CASI Pharmaceuticals corporate directors refer to members of a CASI Pharmaceuticals board of directors. The board of directors generally takes responsibility for the CASI Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of CASI Pharmaceuticals' board members must vote for the resolution. The CASI Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Quan Zhou - Independent DirectorProfile
James Huang - Independent DirectorProfile
Franklin Salisbury - Independent DirectorProfile
Tak Mak - DirectorProfile

Invested in CASI Pharmaceuticals?

The danger of trading CASI Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of CASI Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than CASI Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile CASI Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for analysis

When running CASI Pharmaceuticals price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bond Directory
Find actively traded corporate debentures issued by US companies
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Money Managers
Screen money managers from public funds and ETFs managed around the world
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Is CASI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
27.1 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine CASI Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.